These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 15544505)

  • 1. Acetylcholinesterase inhibitors as a starting point towards improved Alzheimer's disease therapeutics.
    Recanatini M; Valenti P
    Curr Pharm Des; 2004; 10(25):3157-66. PubMed ID: 15544505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multitarget drug design strategy in Alzheimer's disease: focus on cholinergic transmission and amyloid-β aggregation.
    Simoni E; Bartolini M; Abu IF; Blockley A; Gotti C; Bottegoni G; Caporaso R; Bergamini C; Andrisano V; Cavalli A; Mellor IR; Minarini A; Rosini M
    Future Med Chem; 2017 Jun; 9(10):953-963. PubMed ID: 28632446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rationale for the development of cholinesterase inhibitors as anti-Alzheimer agents.
    Lahiri DK; Rogers JT; Greig NH; Sambamurti K
    Curr Pharm Des; 2004; 10(25):3111-9. PubMed ID: 15544501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of novel dual acetylcholinesterase inhibitors with antifibrillogenic activity related to Alzheimer's disease.
    de Almeida JR; Figueiro M; Almeida WP; de Paula da Silva CHT
    Future Med Chem; 2018 May; 10(9):1037-1053. PubMed ID: 29676170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A review on cholinesterase inhibitors for Alzheimer's disease.
    Anand P; Singh B
    Arch Pharm Res; 2013 Apr; 36(4):375-99. PubMed ID: 23435942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Design of acetylcholinesterase inhibitor for Alzheimer's disease therapy: from multi-binding site inhibitors to multi-target directed ligands].
    Yang WC; Sun Q; Yu NX; Zhu XL; Yang GF
    Yao Xue Xue Bao; 2012 Mar; 47(3):313-21. PubMed ID: 22645754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acetylcholinesterase inhibitors as disease-modifying therapies for Alzheimer's disease.
    Muñoz-Torrero D
    Curr Med Chem; 2008; 15(24):2433-55. PubMed ID: 18855672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting beta-amyloid pathogenesis through acetylcholinesterase inhibitors.
    Castro A; Martinez A
    Curr Pharm Des; 2006; 12(33):4377-87. PubMed ID: 17105433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multi-target-directed drug design strategy: from a dual binding site acetylcholinesterase inhibitor to a trifunctional compound against Alzheimer's disease.
    Bolognesi ML; Cavalli A; Valgimigli L; Bartolini M; Rosini M; Andrisano V; Recanatini M; Melchiorre C
    J Med Chem; 2007 Dec; 50(26):6446-9. PubMed ID: 18047264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular modelling approaches to the design of acetylcholinesterase inhibitors: new challenges for the treatment of Alzheimer's disease.
    Muñoz-Muriedas J; Lopez JM; Orozco M; Luque FJ
    Curr Pharm Des; 2004; 10(25):3131-40. PubMed ID: 15544503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benzophenone-based derivatives: a novel series of potent and selective dual inhibitors of acetylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation.
    Belluti F; Bartolini M; Bottegoni G; Bisi A; Cavalli A; Andrisano V; Rampa A
    Eur J Med Chem; 2011 May; 46(5):1682-93. PubMed ID: 21397996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural determinants of the multifunctional profile of dual binding site acetylcholinesterase inhibitors as anti-Alzheimer agents.
    Galdeano C; Viayna E; Arroyo P; Bidon-Chanal A; Blas JR; Muñoz-Torrero D; Luque FJ
    Curr Pharm Des; 2010; 16(25):2818-36. PubMed ID: 20698824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New classes of AChE inhibitors with additional pharmacological effects of interest for the treatment of Alzheimer's disease.
    Villarroya M; García AG; Marco JL
    Curr Pharm Des; 2004; 10(25):3177-84. PubMed ID: 15544507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and Evaluation of Novel Ligustrazine Derivatives as Multi-Targeted Inhibitors for the Treatment of Alzheimer's Disease.
    Wu W; Liang X; Xie G; Chen L; Liu W; Luo G; Zhang P; Yu L; Zheng X; Ji H; Zhang C; Yi W
    Molecules; 2018 Oct; 23(10):. PubMed ID: 30301153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pterostilbene-O-acetamidoalkylbenzylamines derivatives as novel dual inhibitors of cholinesterase with anti-β-amyloid aggregation and antioxidant properties for the treatment of Alzheimer's disease.
    Li Y; Qiang X; Li Y; Yang X; Luo L; Xiao G; Cao Z; Tan Z; Deng Y
    Bioorg Med Chem Lett; 2016 Apr; 26(8):2035-9. PubMed ID: 26947607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis and evaluation of flavonoid derivatives as potential multifunctional acetylcholinesterase inhibitors against Alzheimer's disease.
    Li RS; Wang XB; Hu XJ; Kong LY
    Bioorg Med Chem Lett; 2013 May; 23(9):2636-41. PubMed ID: 23511019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel Multitarget Hybrid Compounds for the Treatment of Alzheimer's Disease.
    Michalska P; Buendia I; Del Barrio L; Leon R
    Curr Top Med Chem; 2017; 17(9):1027-1043. PubMed ID: 27697052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis, in vitro assay, and molecular modeling of new piperidine derivatives having dual inhibitory potency against acetylcholinesterase and Abeta1-42 aggregation for Alzheimer's disease therapeutics.
    Kwon YE; Park JY; No KT; Shin JH; Lee SK; Eun JS; Yang JH; Shin TY; Kim DK; Chae BS; Leem JY; Kim KH
    Bioorg Med Chem; 2007 Oct; 15(20):6596-607. PubMed ID: 17681794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Silibinin inhibits acetylcholinesterase activity and amyloid β peptide aggregation: a dual-target drug for the treatment of Alzheimer's disease.
    Duan S; Guan X; Lin R; Liu X; Yan Y; Lin R; Zhang T; Chen X; Huang J; Sun X; Li Q; Fang S; Xu J; Yao Z; Gu H
    Neurobiol Aging; 2015 May; 36(5):1792-807. PubMed ID: 25771396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A step further towards multitarget drugs for Alzheimer and neuronal vascular diseases: targeting the cholinergic system, amyloid-β aggregation and Ca(2+) dyshomeostasis.
    León R; Marco-Contelles J
    Curr Med Chem; 2011; 18(4):552-76. PubMed ID: 21143111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.